{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T22:54:30Z","timestamp":1783464870193,"version":"3.55.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T00:00:00Z","timestamp":1690243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72074005"],"award-info":[{"award-number":["72074005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00277-023-05371-7","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T20:38:11Z","timestamp":1690317491000},"page":"2765-2777","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A prediction model for severe hematological toxicity of BTK inhibitors"],"prefix":"10.1007","volume":"102","author":[{"given":"Dan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaiwei","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongsheng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,25]]},"reference":[{"issue":"3","key":"5371_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71(3):209\u2013249","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"5371_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70(1):7\u201330","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"5371_CR3","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41375-020-01072-6","volume":"35","author":"T Wen","year":"2021","unstructured":"Wen T, Wang J, Shi Y, Qian H, Liu P (2021) Inhibitors targeting Bruton\u2019s tyrosine kinase in cancers: drug development advances. Leukemia 35(2):312\u2013332","journal-title":"Leukemia"},{"key":"5371_CR4","doi-asserted-by":"publisher","first-page":"114232","DOI":"10.1016\/j.ejmech.2022.114232","volume":"233","author":"F Ran","year":"2022","unstructured":"Ran F, Liu Y, Xu Z, Meng C, Yang D, Qian J et al (2022) Recent development of BTK-based dual inhibitors in the treatment of cancers. Eur J Med Chem 233:114232","journal-title":"Eur J Med Chem"},{"key":"5371_CR5","doi-asserted-by":"publisher","first-page":"720704","DOI":"10.3389\/fonc.2021.720704","volume":"11","author":"SM O\u2019Brien","year":"2021","unstructured":"O\u2019Brien SM, Brown JR, Byrd JC, Furman RR, Ghia P, Sharman JP et al (2021) Monitoring and managing BTK inhibitor treatment-related adverse events in clinical practice. Front Oncol 11:720704","journal-title":"Front Oncol"},{"issue":"19","key":"5371_CR6","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood-2016-12-737346","volume":"129","author":"PM Barr","year":"2017","unstructured":"Barr PM, Brown JR, Hillmen P, O\u2019Brien S, Barrientos JC, Reddy NM et al (2017) Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL\/SLL. Blood 129(19):2612\u20132615","journal-title":"Blood"},{"key":"5371_CR7","first-page":"100751","volume":"33","author":"C \u00d6zt\u00fcrk","year":"2021","unstructured":"\u00d6zt\u00fcrk C, Validyev D, Becher UM, Weber M, Nickenig G, Tiyerili V (2021) A novel scoring system to estimate chemotherapy-induced myocardial toxicity: risk assessment prior to non-anthracycline chemotherapy regimens. Int J Cardiol Heart Vasc 33:100751","journal-title":"Int J Cardiol Heart Vasc"},{"issue":"8","key":"5371_CR8","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1093\/annonc\/mdr580","volume":"23","author":"G Dranitsaris","year":"2012","unstructured":"Dranitsaris G, Vincent MD, Yu J, Huang L, Fang F, Lacouture ME (2012) Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib. Ann Oncol 23(8):2103\u20132108","journal-title":"Ann Oncol"},{"issue":"10","key":"5371_CR9","doi-asserted-by":"publisher","first-page":"e002545","DOI":"10.1136\/jitc-2021-002545","volume":"9","author":"SP Heilbroner","year":"2021","unstructured":"Heilbroner SP, Few R, Neilan TG, Mueller J, Chalwa J, Charest F et al (2021) Predicting cardiac adverse events in patients receiving immune checkpoint inhibitors: a machine learning approach. J Immunother Cancer 9(10):e002545","journal-title":"J Immunother Cancer"},{"key":"5371_CR10","doi-asserted-by":"crossref","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KGM (2015) Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 350(jan07 4):g7594\u2013g7594","DOI":"10.1136\/bmj.g7594"},{"issue":"6","key":"5371_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","volume":"28","author":"G Dranitsaris","year":"2017","unstructured":"Dranitsaris G, Molassiotis A, Clemons M, Roeland E, Schwartzberg L, Dielenseger P et al (2017) The development of a prediction tool to identify cancer patients at high risk for chemotherapyinduced nausea and vomiting. Ann Oncol 28(6):1260\u20131267","journal-title":"Ann Oncol"},{"issue":"6","key":"5371_CR12","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1109\/TAC.1974.1100705","volume":"19","author":"H Akaike","year":"1974","unstructured":"Akaike H (1974) A new look at the statistical model identification. IEEE Trans Autom Control 19(6):716\u2013723","journal-title":"IEEE Trans Autom Control"},{"issue":"11","key":"5371_CR13","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/S1470-2045(05)70394-6","volume":"6","author":"G Dranitsaris","year":"2005","unstructured":"Dranitsaris G, Clemons M, Verma S, Lau C, Vincent M (2005) Chemotherapy-induced anaemia during adjuvant treatment for breast cancer: development of a prediction model. Lancet Oncol 6(11):856\u2013863","journal-title":"Lancet Oncol"},{"issue":"14","key":"5371_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","unstructured":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med 329(14):987\u2013994","journal-title":"N Engl J Med"},{"key":"5371_CR15","doi-asserted-by":"publisher","first-page":"630942","DOI":"10.3389\/fcell.2021.630942","volume":"9","author":"HY Estupi\u00f1\u00e1n","year":"2021","unstructured":"Estupi\u00f1\u00e1n HY, Bergl\u00f6f A, Zain R, Smith CIE (2021) Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol 9:630942","journal-title":"Front Cell Dev Biol"},{"issue":"6","key":"5371_CR16","first-page":"354","volume":"98","author":"J Phillips","year":"2018","unstructured":"Phillips J, Henderson AC (2018) Hemolytic anemia: evaluation and differential diagnosis. Am Fam Physician 98(6):354\u2013361","journal-title":"Am Fam Physician"},{"issue":"11","key":"5371_CR17","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1182\/blood.2019001160","volume":"134","author":"CS Tam","year":"2019","unstructured":"Tam CS, Trotman J, Opat S, Burger JA, Cull G, Gottlieb D et al (2019) Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood 134(11):851\u2013859","journal-title":"Blood"},{"issue":"5","key":"5371_CR18","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/S0002-9343(02)01036-7","volume":"112","author":"GH Lyman","year":"2002","unstructured":"Lyman GH, Kuderer NM, Djulbegovic B (2002) Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis. Am J Med 112(5):406\u2013411","journal-title":"Am J Med"},{"key":"5371_CR19","doi-asserted-by":"publisher","first-page":"931495","DOI":"10.3389\/fphar.2022.931495","volume":"13","author":"Z Song","year":"2022","unstructured":"Song Z, Ma L, Bao L, Ma Y, Yang P, Jiang D et al (2022) Toward therapeutic drug monitoring of lenalidomide in hematological malignancy? Results of an observational study of the exposure-safety relationship. Front Pharmacol 13:931495","journal-title":"Front Pharmacol"},{"key":"5371_CR20","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.critrevonc.2019.02.001","volume":"136","author":"S Paydas","year":"2019","unstructured":"Paydas S (2019) Management of adverse effects\/toxicity of ibrutinib. Crit Rev Oncol Hematol 136:56\u201363","journal-title":"Crit Rev Oncol Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05371-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05371-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T10:05:08Z","timestamp":1694253908000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05371-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,25]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5371"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05371-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,25]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The studies involving human participants were reviewed and approved by the Medical Science Research Ethics Committee of Peking University Third Hospital (No. M2022427). The requirement for informed patient consent was waived, because it was determined that this study did not directly involve human participants and was a secondary analysis of existing data of deidentified patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors declared no competing interests for this work.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}